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Abstract
Integrin α6β4 is mostly expressed in epithelial tissues and endo-
thelial and Schwann cells. Expression of α6β4 is increased in many
epithelial tumours, implicating its involvement in tumour malig-
nancy. Moreover, this integrin activates several key signalling
molecules in carcinoma cells, but its ability to activate the
phosphatidylinositol 3-kinase/Akt pathway is among the
mechanisms by which α6β4 integrin regulates tumour behaviour. In
this review we discuss the biological and clinical features of α6β4
integrin that allow it to promote tumour survival and progression of
mammary tumours.
Introduction
Integrins belong to a family of heterodimer transmembrane
receptors whose major function is to mediate adhesion and
migration through extracellular matrix components [1,2]. They
also regulate other processes such as cell proliferation,
growth and differentiation [3]. Studies conducted during the
past 10 years have provided evidence that integrins are
involved in mechanisms that influence tumour progression by
activating various intracellular signalling pathways [4].
Among the integrin family of receptors, α6β4 integrin was
initially identified as tumour-specific antigen-180 [5]. A
subsequent study [6] demonstrated the true identity of
tumour-specific antigen-180 to be α6β4 integrin. In most
epithelial tissues, including mammary epithelium, the
distribution of α6β4 integrin is restricted to the basal layer
[7,8], where it participates in the formation and stabilization of
hemidesmosomes [9]. Most epithelial tumours lack
hemidesmosomes, and α6β4 integrin is distributed diffusely
over the cell surface; the markedly increased expression of
α6β4 integrin in this setting suggests that it is involved in
tumour progression [10,11]. Direct involvement of this integrin
in tumour progression was first demonstrated by the finding
that de novo expression of the β4 integrin subunit increases
the invasive capacity of β4-negative colon carcinoma cells
[12]. In mammary tumour cells it has been demonstrated that
α6β4 integrin, cooperating with Erb family members, plays an
important role in regulating cancer behaviour [10].
Breast cancer is one of the most heterogeneous carcinomas
in terms of metastatic capacity, expression of hormone
receptors and responsiveness to treatment. In women it is the
most common form of cancer and it is the second leading
cause of cancer mortality (after lung cancer). It has been
demonstrated that in many breast cancers the effect of
therapy can be abrogated by high levels of ErbB-2 and
vigorous activation of the phosphatidylinositol 3-kinase (PI3K)
pathway [13]. Many breast cancer cell lines also exhibit high
levels of expression of α6β4 integrin; in these cell lines it has
been observed that overexpression of this integrin results in
potent activation of specific signalling pathways, especially
the PI3K/Akt pathway [14]. These studies have revealed a
specific function of α6β4 integrin in tumours and have
elucidated the mechanisms by which this integrin promotes
the survival and progression of mammary tumours.
Role of α α6β β4 integrin in cell migration
The altered expression of α6β4 integrin in tumour cell lines of
epithelial origin suggests that this integrin promotes tumour
progression and spread [14]. Only during the past few years
has it become clear how α6β4 integrin contributes to these
tumour behaviours. The large cytoplasmic tail of the β4
subunit, which comprises more than 1,000 amino acids, is
unique among the integrin family members [15].
Much progress has been made in identifying specific
domains that mediate functions such as adhesion and
migration in normal and tumour cells [16,17]. Chemotactic
migration of carcinoma cells on laminin-1 requires not only
the formation of F-actin-rich cell protrusions, which mediate
α6β4-dependent cell migration, but also disruption of
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hemidesmosomes by protein kinase C [18]. Moreover,
stimulation of epidermal growth factor causes mobilization of
α6β4 integrin from the hemidesmosomes and increases
formation of lamellipodia and membrane ruffles that contain
α6β4 integrin [18,19]. It has also been shown in keratinocytes
that spreading on laminin-5 activates Ron, which results in a
protein kinase C dependent translocation of α6β4 integrin
from hemidesmosome to lamellipodia [20]; this corroborates
previous work in suggesting that α6β4 integrin, by helping to
stabilize dynamic structures, promotes migration. In addition,
the ability of α6β4 integrin to regulate the expression of genes
such as the transcription factor NFAT [21] and the mitogen
autotaxin/ENPP2 factor [22] could be among the mechanism
through which the integrin can promote breast cancer cell
motility.
Another mechanism by which α6β4 integrin could be involved
in breast cancer cell invasion is dependent on hypoxia [23].
Hypoxia causes a marked increase in surface expression of
α6β4 integrin in mammary tumour cells, which modulates their
motility and ability to invade.
Role of α α6β β4 integrin in PI3K-dependent
tumour survival
As in keratinocytes, overexpression of α6β4 integrin in breast
cancer cells promotes motility by specifically activating PI3K
[24]. In particular, regulation of PI3K by α6β4 stimulation is
required for the formation of motility structures and for
activation of Rac to promote invasion. It has also been
reported that α6β4 integrin promotes survival by activating the
PI3K/Akt pathway and that this function may be dependent
on p53 status [25]. Specifically, it has been demonstrated
that α6β4 can promote PI3K/Akt-dependent survival of p53-
deficent mammary tumour cells. Moreover, in response to
α6β4 ligation for the recruitment of PI3K on the plasma
membrane are implicated two insulin receptor substrate (IRS)
members, namely IRS-1 and IRS-2, as adaptor proteins, that
mediate the α6β4 -dependent PI3K activation [26].
A study conducted in our laboratory [27] provided the first
evidence that in mammary tumour cells α6β4 associates with
ErbB-2, the orphan receptor of the epidermal growth factor
receptor (EGFR) family, which is frequently found to be highly
expressed in mammary tumours. A subsequent study
conducted in a NIH3T3 cell model system [28] demonstrated
that the β4 cytoplasmic tail is required in this interaction and
that both α6β4 and ErbB-2 molecules are required for PI3K-
dependent invasion. Both β4 integrin subunit and ErbB-2 lack
the consensus sequence to bind p85, the regulatory subunit
of PI3K; this suggests that involvement of another EGFR
family member is required to activate PI3K. Among EGFR
family members, the ErbB-2/ErbB-3 heterodimer is the most
potent activator of PI3K. α6β4 Integrin and ErbB-2/ErbB-3
have been implicated in breast cancer progression and
metastasis [29,30], findings that suggest a role for the ErbB-
3 molecule in α6β4/ErbB-2 cooperation. Indeed, α6β4 regu-
lates the translation of ErbB-3 protein in mammary cells,
which results in significant induction of ErbB-2/ErbB-3
heterodimerization and consequent activation of the PI3K/Akt
survival pathway [31]. Moreover, activation of PI3K/Akt
pathway mediated by α6β4 ligation is inhibited upon ErbB-3
depletion, indicating that the survival function of α6β4 integrin
is dependent on ErbB-3.
These data are apparently in contrast with the finding that
clustering of α6β4 under adherent conditions does not result
in significantly increased PI3K activity [32]. However, these
latter findings were obtained in a cell line that expresses high
levels of α6β4 integrin and that does not express ErbB-3
receptor. A probable explanation for the discrepant obser-
vations is that the cells used by Gilcrease and coworkers
[32] express the Nrdp1 ubiquitin ligase, which promotes
ErbB-3 degradation [33].
Previous work [34] demonstrated that α6β4, through the
PI3K/Akt pathway, phosphorylates and inactivates 4E-BP1 (a
translational repressor), which in turn stimulates production of
vascular endothelial growth factor (VEGF) and promotes
survival of breast cancer cells. The VEGF is an autocrine
survival factor for breast carcinoma cells [34], and because
α6β4 cooperates with EGFR members to promote survival of
breast cancer cells [31] we cannot exclude the possibility
that α6β4-mediated ErbB-2/ErbB-3 signalling promotes
breast carcinoma survival by elevating VEGF expression. It is
interesting to note that the crosstalk between  α6β4 integrin
and EGFR family members is strong. For example, it was
recently shown that α6β4 integrin also regulates the
translation of ErbB-2 protein and that expression of α6β4
integrin is necessary to regulate Ras activation [35]. More-
over, H-Ras promotes carcinoma invasion by E2F-dependent
regulation of α6β4 integrin [36]. Overexpression of E2F family
members increases levels of the β4 subunit both at
transcriptional and protein levels, resulting in markedly
increased invasion.
Role of α α6β β4 integrin in breast cancer
progression
A specific role for α6β4 integrin in breast cancer progression
and tumourigenesis was recently demonstrated by the finding
that depletion of α6β4 integrin, by RNA interference, strongly
reduces in vitro and in vivo tumourigenicity [37,38]. Interes-
tingly, loss of α6β4 integrin reduces significantly the tumouri-
genicity of mammary tumour cells, reducing the production of
VEGF in vivo. This finding is in agreement with previous data
indicating that α6β4 integrin regulates VEGF translation [34],
supporting the important role played by α6β4 integrin in
sustaining the survival of mammary tumour cells [25]. Loss of
α6β4 integrin also results in significant downregulation of
PI3K/Akt activity [38].
It has been found that in the absence of hormone β4-depleted
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(page number not for citation purposes)
45% with to hormone therapy [38]. This finding indicates that
α6β4 integrin plays a role in promoting survival in mammary
tumour cells in the absence of hormone. Recently, it has been
described that mice carrying a deletion of the c-terminal
region of the β4 tail evidenced that α6β4 integrin promotes
mammary tumourigenesis [39]. In vivo, cooperation between
α6β4 integrin and ErbB-2 enhances activation of the
transcription factors STAT3 and c-Jun, which results in
disrupted epithelial polarity and hyperproliferation,
respectively [39].
The α6β4 integrin cooperates with other tyrosine kinases such
as c-met (a hepatocyte growth factor receptor) to promote
invasion [40]. Stimulation with hepatocyte growth factor
(c-met kinase) transphosphorylates β4, which associates with
Shc and PI3K, potentiating hepatocyte growth factor-
triggered signalling on both Ras and PI3K dependent
pathways. The same group [41] recently found that over-
expression of β4 subunit is sufficient to transform rodent fibro-
blasts, increases the in vitro growth of mammary tumour cells,
and induces tumourigenicity in nude mice, whereas depletion
of α6β4 integrin abrogates the transformed phenotype.
Altogether, these studies demonstrate that the crosstalk
between α6β4 integrin and receptor tyrosine kinase signalling
is strong and contributes to increased ability of mammary
tumour cells to grow and invade.
In vivo expression and localization of α α6β β4
integrin in breast cancer
Although expression of α6β4 integrin  in vivo has not been
evaluated extensively, the in vivo data obtained in the
following studies are in agreement with in vitro findings.
The first study to analyze the distribution of α6β4 integrin in
human carcinomas [42] identified high levels of expression in
various epithelial tumours. Similar findings were reported from
a study that analyzed the β4 subunit in normal, hyperplastic
and neoplastic breast cancers [43]. Among the tumours
analyzed, immunohistochemical study found that mucinous
carcinomas are highly positive for β4 expression, whereas
luminal cells of normal ducts and acini as well as
fibroadenocystic tissue exhibit rare, weak reactivity.
In contrast to previous findings, an analysis conducted in a
limited number of breast cancers [44] demonstrated loss of
α6β4 integrin in grade III ductal carcinoma (7/11 cases)
whereas most of grade I and II carcinomas analyzed were
positive (6/8 cases). Even though this study is restricted to a
small number of mammary tumours and the results obtained
did not achieve statistical significance, it revealed marked de-
regulation of integrin expression that correlated with loss of
polarization, which is a characteristic feature of epithelial
tumours. Similar results were obtained in an analysis of the
expression of α6 and β4 subunits in primary and metastatic
breast cancers [45]. Interestingly, the findings obtained
indicate that, as expected, in normal mammary gland both
subunits colocalize at the basolateral aspect of the
epithelium, which remains unchanged in benign breast
lesions; in contrast, in primary carcinomas expression of both
chains is reduced and restricted over the cell surface. The
same study revealed that α6β4 integrin is present at
lymphonodal foci, but that the level of expression is less in
metastases to the pleural cavity and parenchymal tissues.
Moreover, lack of laminin and collagen type IV correlates in
these tumours with reduced α6β4 expression [45].
More recently, a study conducted in 119 tumours from
patients with invasive breast carcinoma [46] demonstrated
that low levels of expression of α6 subunit correlate with
survival, whereas high levels of expression correlate with
significantly reduced survival. Indeed, elevated expression of
α6 was present in 90% of cases with distant metastases,
indicating that this integrin plays a role in tumour progression.
In agreement with the findings of that study, an analysis of
α6β4 integrin in 80 patients with breast carcinoma [47]
revealed that 36 of these tumours expressed high levels of β4
subunit, with a significant association between expression of
α6 subunit and production of laminin by tumour cells. That
study demonstrated, for the first time, that concomitant
expression of α6β4 integrin and laminin production has clear
prognostic value, suggesting that these molecules mediate
signalling events that are important for tumour progression.
An  in situ hybridization study was recently conducted in
which  β4 mRNA expression was evaluated in paraffin-
embedded sections of tissue from 25 patients with invasive
breast carcinoma, and compared with immunohistochemical
findings from frozen sections derived from same tumours
[48]. It revealed that all cases positive for β4 protein also
expressed  β4 mRNA; three cases in which β4 mRNA was
detected did not express β4 at the protein level. Using in situ
hybridization, the same group analyzed β4 subunit mRNA
expression in early breast cancer and correlated their findings
with both tumour size and nuclear grade [49]. They also
analyzed the expression of laminin-5 (the major substrate for
α6β4 integrin in epithelial tissue) in these tumours. They
observed a strong correlation between β4 mRNA expression
and tumour size and nuclear grade, but correlation between
β4 and laminin-5 expression was not found to have prognostic
significance [50].
All of these studies, in agreement with literature published
during the past 2 years, strongly support a role for α6β4
expression in promoting tumour progression. These studies
also indicate that the biological role played by α6β4 in
mammary tumours is complex; studies should be extended to
other molecules that may cooperate with α6β4 integrin to
render tumours more aggressive. These studies could help us
to determine whether α6β4 integrin should be considered an
early marker of tumourigenicity and to evaluate tumour
prognosis better.
Available online http://breast-cancer-research.com/content/9/1/203Conclusion
Both experimental data and in vivo studies discussed in this
review indicate that α6β4 integrin plays a major role in
mediating the aggressiveness of mammary tumours.
Metastasis is a complex process that involves many mole-
cules and many biochemical alterations in tumour cells.
Integrin  α6β4 is a key molecule in this process, but much
more needs to be learned about the contribution of this
integrin to tumour progression. There is much cooperation
between  α6β4 integrin and EGFR family members;
furthermore, this integrin can modulate the expression of
growth factors and growth factor receptors that are involved
in tumour progression. Acknowledgement of the intimate
relationships between these molecules could represent an
aid in determining prognosis, could guide management
decisions, and could facilitate development of drugs with
novel targets.
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